1.37
23.42%
0.26
Cumberland Pharmaceuticals Inc stock is traded at $1.37, with a volume of 2.13M.
It is up +23.42% in the last 24 hours and up +12.30% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
See More
Previous Close:
$1.11
Open:
$1.12
24h Volume:
2.13M
Relative Volume:
32.96
Market Cap:
$15.65M
Revenue:
$37.79M
Net Income/Loss:
$-10.38M
P/E Ratio:
-10.54
EPS:
-0.13
Net Cash Flow:
$-1.00M
1W Performance:
+25.69%
1M Performance:
+12.30%
6M Performance:
-11.61%
1Y Performance:
-17.96%
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
2525 WEST END AVENUE, NASHVILLE,, TN
Compare CPIX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
1.37 | 15.65M | 37.79M | -10.38M | -1.00M | -0.13 |
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-12-12 | Reiterated | UBS | Neutral |
Feb-01-11 | Reiterated | UBS | Neutral |
Dec-16-10 | Downgrade | UBS | Buy → Neutral |
Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
Aug-17-10 | Reiterated | Morgan Joseph | Buy |
Aug-17-10 | Reiterated | UBS | Buy |
May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by Analysts at StockNews.com - Defense World
Cumberland Pharma stock hits 52-week low at $1.04 By Investing.com - Investing.com Nigeria
Cumberland Pharma stock hits 52-week low at $1.04 - Investing.com
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2024 Earnings Call Transcript - MSN
Corneal Ulcer Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World
Ibuprofen Injection Shows Better Real-World Outcomes in Comparative Study - Pharmacy Practice News
Cumberland Pharma stock hits 52-week low at $1.07 - Investing.com
Cumberland Pharma stock hits 52-week low at $1.07 By Investing.com - Investing.com UK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Cumberland Partners Ltd - MarketBeat
Ibuprofen injection exhibits kidney safety with cost benefits over ketorolac: Study - Medical Dialogues
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) - Yahoo Finance UK
Cumberland Pharmaceuticals Inc. (CPIX) Quarterly 10-Q Report - Quartzy
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... By GuruFocus - Investing.com Canada
Cumberland: Q3 Earnings Snapshot - mySA
Cumberland Pharmaceuticals Reports Q3 2024 Earnings and Developments - TipRanks
Cumberland Pharmaceuticals Inc (CPIX) Reports Q3 2024 Revenue of $9.1 Million and EPS Loss of $0.11 - GuruFocus.com
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update - StockTitan
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire UK
Cumberland's Ifetroban Secures Dual FDA Designations for Rare DMD Treatment | CPIX Stock | CPIX Stock News - StockTitan
Cumberland Pharmaceuticals director James Jones buys $1,827 in stock - Investing.com
Cumberland Pharmaceuticals CEO A.J. Kazimi buys $1,827 in stock - Investing.com
Cumberland Pharmaceuticals director Caroline Young acquires $913 in stock - Investing.com
Cumberland Pharmaceuticals director James Jones buys $1,827 in stock By Investing.com - Investing.com UK
Cumberland's Caldolor Shows 78% Better Safety Than Ketorolac in Landmark 150K Patient Study | CPIX Stock News - StockTitan
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS - Citizentribune
Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the Field | DelveInsight - PR Newswire UK
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? - Simply Wall St
Cumberland Pharma stock hits 52-week low at $1.18 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.18 - Investing.com India
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, Share Analysis And Growth Statistics By 2033 - WhaTech
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - India Shorts
Bacterial Pneumonia Market Expected to See Prominent Growth - openPR
Complicated Skin And Skin Structure Infections Drugs Market Insights Discussed Regarding Share, Trends, Siz... - WhaTech
Idiopathic Pulmonary Fibrosis Ipf Market Size and Growth - openPR
Scleroderma Market to Witness Significant Growth by 2031 | Pfizer, Inc., Sanofi, GlaxoSmithKline plc - openPR
Cumberland Pharma stock hits 52-week low at $1.19 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.19 - Investing.com
Vasopressin Market Huge Growth in Future Scope 2024-2031 | Par - openPR
Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Cumberland Pharmaceuticals (NASDAQ:CPIX) Research Coverage Started at StockNews.com - Defense World
Scleroderma Diagnostics and Therapeutics Market – 37% of Growth to Originate from APAC -Actelion Pharmaceuticals, Inc., – உங்கள் குரல் - உங்கள் குரல்
Cooling Paste Market Growing Rapidly by-Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pigeon, New Tac Kasei, Sato – IndiaPolitics.com - IndiaPolitics.com
Ibuprofen Injection Industry to Witness Massive Growth (2024-2034) |Cumberland Pharmaceuticals, CSL Limited, Akorn, Inc. – IndiaPolitics.com - IndiaPolitics.com
Cooling Paste Industry to Witness an Outstanding Growth by 2030 |Kobayashi Pharmaceutical, Hisamitsu Pharmaceutical, Pig – IndiaPolitics.com - IndiaPolitics.com
Drugs for Xerostomia Market Future Developments – Concordia, AMICI, Aurobindo Pharma Ltd, Impax Labs - Cauverynews
Burn Pain Market Expected to Experience Major Growth by 2034, - openPR
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):